简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2021-05-06 10:18 Exscientia Announces Investment of up to $525M
2021-05-06 10:15 Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
2021-04-30 16:50 Takeda Manufacturing Facilities in Japan and Ireland Recognized With Category Awards for 2021 Facilities of the Year
2021-04-30 14:37 VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
2021-04-29 14:17 Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
2021-04-29 09:52 Ultivue Announces $50M Financing Round
2021-04-29 09:10 Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
2021-04-28 17:33 Siemens Releases gPROMS FormulatedProducts 2.0 – New Application Areas and Key Usability Enhancements
2021-04-28 17:29 Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
2021-04-28 13:11 First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
2021-04-27 14:36 SpeeDx Receives CE-IVD Mark for PlexPCR® SARS-CoV-2
2021-04-26 09:24 LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021
2021-04-26 09:19 Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
2021-04-26 09:08 LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis
2021-04-23 19:07 MSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences Indexes
2021-04-23 13:34 Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases
2021-04-23 10:14 Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
2021-04-21 16:42 Pacific Telecommunications Council Announces the Call for Participation for Its 44th Annual Conference
2021-04-21 15:54 Take ‘VOW’ to Protect All Humanity: ‘Vaccinate Our World!’
2021-04-21 13:27 PTT Invests in Lotus Pharmaceutical's Strategic Partnership in South East Asia

Business Wire Weibo

Press Releases

Latest Releases